Inovio loses AstraZeneca-partnered cancer vaccine pact; reacquires INO-3112 rights

INOVIO PHARMACEUTICALS, INC.

MedImmune (AstraZeneca R&D) terminated INO-3112/MEDI0457 collaboration effective Oct 28, 2021.
Inovio reacquires all rights to INO-3112; forfeits future milestone payments and royalties.
MedImmune continues Phase 2 HNSCC trial; final data cut-off completed, study report by end of 2022.
Revenue from the agreement was minimal: $33k in H1 2021, $171k in 2020, $2M in 2019.
Company states it is not substantially dependent on the terminated collaboration agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.